Literature DB >> 7605432

Support for trials of promising medications through the Pharmaceutical Benefits Scheme. A proposal for a new authority category.

P P Glasziou1.   

Abstract

I propose a new authority category for the Pharmaceutical Benefits Scheme (PBS)--authority to prescribe only within a controlled trial. This would benefit both the PBS and the pharmaceutical companies, but the main winners would be the Australian population, who would obtain better value for money spent by the PBS. Drugs which show promise, but for which conclusive evidence of advantage over standard therapy is lacking, or drugs for new indications, could be prescribed within a randomised trial. PBS support would fund a substantial portion of the trial costs. This proposal would greatly boost local and international investment in Australian medical research.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7605432

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  6 in total

1.  The need for pharmacoeconomic evaluations in the NHS.

Authors:  J P Griffin
Journal:  Pharmacoeconomics       Date:  1998-09       Impact factor: 4.981

2.  A role for two-stage pharmacoeconomic appraisal? Is there a role for interim approval of a drug for reimbursement based on modelling studies with subsequent full approval using phase III data?

Authors:  Suzanne Hill; Nick Freemantle
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

3.  Making a decision to wait for more evidence: when the National Institute for Health and Clinical Excellence recommends a technology only in the context of research.

Authors:  Kalipso Chalkidou; Andrew Hoy; Peter Littlejohns
Journal:  J R Soc Med       Date:  2007-10       Impact factor: 5.344

Review 4.  Finding information on clinical effectiveness.

Authors:  J Glanville; M Haines; I Auston
Journal:  BMJ       Date:  1998-07-18

5.  A flow diagram to facilitate selection of interventions and research for health care.

Authors:  L Irwig; M Zwarenstein; A Zwi; I Chalmers
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

6.  Comparing treatments.

Authors:  D Henry; S Hill
Journal:  BMJ       Date:  1995-05-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.